Sign In
Buy RPRX
$53.57
+0.610 (+1.15%)
At Close: Jun 22, 2026
Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation
01:00pm, Tuesday, 21'st Apr 2026
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the launch of the Royalty Pharma Translational Prize, which recognizes exceptional achievements in transl
Royalty Pharma Declares Second Quarter 2026 Dividend
08:30am, Friday, 17'th Apr 2026
NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2026 of $0.235 per Class A ord
Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026
04:15pm, Wednesday, 15'th Apr 2026
NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2026 financial results on Wednesday, May 6, 2026 before the U.S. fi
Can Royalty Pharma (RPRX) Keep the Earnings Surprise Streak Alive?
01:11pm, Tuesday, 14'th Apr 2026
Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Aberdeen Group plc Acquires 98,191 Shares of Royalty Pharma PLC $RPRX
03:07am, Monday, 06'th Apr 2026
Aberdeen Group plc grew its stake in shares of Royalty Pharma PLC (NASDAQ: RPRX) by 17.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. Th
Royalty Pharma (NASDAQ:RPRX) CFO Terrance Coyne Sells 34,791 Shares of Stock
04:48am, Friday, 03'rd Apr 2026
Royalty Pharma PLC (NASDAQ: RPRX - Get Free Report) CFO Terrance Coyne sold 34,791 shares of the company's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $
Royalty Pharma and J&J partner to develop autoimmune treatment
09:14am, Monday, 30'th Mar 2026
Royalty Pharma said on Monday it has signed a $500 million research and development agreement with Johnson & Johnson to advance an experimental antibody treatment for autoimmune diseases.
Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases
07:15am, Monday, 30'th Mar 2026
NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of $500 million
SG Americas Securities LLC Buys 234,629 Shares of Royalty Pharma PLC $RPRX
05:22am, Monday, 30'th Mar 2026
SG Americas Securities LLC lifted its stake in Royalty Pharma PLC (NASDAQ: RPRX) by 438.0% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exch
Terrance Coyne Sells 34,791 Shares of Royalty Pharma (NASDAQ:RPRX) Stock
04:22am, Friday, 27'th Mar 2026
Royalty Pharma PLC (NASDAQ: RPRX - Get Free Report) CFO Terrance Coyne sold 34,791 shares of the company's stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average
Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence
07:15am, Monday, 23'rd Mar 2026
NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Lucas Glass as Head of Artificial Intelligence, effective April 2026. Lucas will lead
Royalty Pharma Announces Expansion of Leadership Team
04:01pm, Tuesday, 17'th Mar 2026
Greg Butz joins Royalty Pharma as Executive Vice President, Partnering & Investments Greg Butz joins Royalty Pharma as Executive Vice President, Partnering & Investments
Elo Mutual Pension Insurance Co Purchases 13,856 Shares of Royalty Pharma PLC $RPRX
03:58am, Friday, 06'th Mar 2026
Elo Mutual Pension Insurance Co lifted its position in shares of Royalty Pharma PLC (NASDAQ: RPRX) by 57.4% during the undefined quarter, according to the company in its most recent 13F filing with th
Royalty Pharma plc (RPRX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
03:52pm, Tuesday, 03'rd Mar 2026
Royalty Pharma plc (RPRX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform
07:00am, Monday, 02'nd Mar 2026
NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be
